Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc. News
ALX Oncology Holdings Inc. Quantitative Score
About ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hodgkin's lymphoma, as well as a range of solid tumor indications, including head and neck squamous cell carcinoma, human epidermal growth factor receptor 2 (HER2) positive gastric/gastroesophageal junction carcinoma, HER2-expressing breast cancer, and other solid tumors. The company's pre-clinical products include ALTA-002, a SIRPa TRAAC that offers ways to engage the innate and adaptive immune response to cancer. ALX Oncology Holdings Inc. has a collaboration agreement with Merck for a Phase 2 trial evaluating ALX148 in combination with pembrolizumab with and without chemotherapy in patients with head and neck cancer; Zymeworks on a Phase 1 trial evaluating ALX148 with the HER2-targeting bispecific antibody zanidatamab in patients with HER2-expressing breast cancer and other solid tumors; and Tallac Therapeutics for the development, manufacturing and commercialization of a novel class of cancer immunotherapeutics. It also has a license agreement with Selexis SA and Crystal Bioscience, Inc. The company was founded in 2015 and is headquartered in South San Francisco, California.
ALX Oncology Holdings Inc. Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
ALX Oncology Holdings Inc. Financials
Table Compare
Compare ALXO metrics with: | |||
|---|---|---|---|
Earnings & Growth | ALXO | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | ALXO | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | ALXO | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | ALXO | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
ALX Oncology Holdings Inc. Income
ALX Oncology Holdings Inc. Balance Sheet
ALX Oncology Holdings Inc. Cash Flow
ALX Oncology Holdings Inc. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Neutral |
| Return on Equity | Strong Sell |
| Return on Assets | Strong Sell |
| Debt/Equity Ratio | Sell |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Strong Buy |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Historical Market Cap
Shares Outstanding
ALX Oncology Holdings Inc. Executives
| Name | Role |
|---|---|
| Mr. Jason W. Lettmann | Chief Executive Officer & Director |
| Ms. Shelly Pinto CPA | Senior Vice President of Finance & Chief Accounting Officer |
| Dr. Alan Bart Sandler M.D. | Chief Medical Officer |
| Dr. Lin Yeong-Liang M.D., M.S. | Senior Vice President of Drug Safety & Pharmacovigilance |
| Ms. Sue Naim | Senior Vice President of Clinical Operations |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Mr. Jason W. Lettmann | Chief Executive Officer & Director | Male | 1977 | 992.6K |
| Ms. Shelly Pinto CPA | Senior Vice President of Finance & Chief Accounting Officer | Female | 1977 | 526.2K |
| Dr. Alan Bart Sandler M.D. | Chief Medical Officer | 1957 | 13.66K | |
| Dr. Lin Yeong-Liang M.D., M.S. | Senior Vice President of Drug Safety & Pharmacovigilance | -- | ||
| Ms. Sue Naim | Senior Vice President of Clinical Operations | Female | -- |
ALX Oncology Holdings Inc. Insider Trades
| Date | 14 Oct |
| Name | Pinto Shelly |
| Role | SVP, FINANCE AND CAO |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 140000 |
| Date | 14 Oct |
| Name | Lettmann Jason |
| Role | CHIEF EXECUTIVE OFFICER |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 597500 |
| Date | 14 Oct |
| Name | Shantharam Harish |
| Role | Chief Financial Officer |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 198750 |
| Date | 17 Sep |
| Name | Klencke Barbara |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 300000 |
| Date | 16 Sep |
| Name | Lettmann Jason |
| Role | CHIEF EXECUTIVE OFFICER |
| Transaction | Acquired |
| Type | P-Purchase |
| Shares | 21070 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 14 Oct | Pinto Shelly | SVP, FINANCE AND CAO | Acquired | A-Award | 140000 |
| 14 Oct | Lettmann Jason | CHIEF EXECUTIVE OFFICER | Acquired | A-Award | 597500 |
| 14 Oct | Shantharam Harish | Chief Financial Officer | Acquired | A-Award | 198750 |
| 17 Sep | Klencke Barbara | Director | Acquired | A-Award | 300000 |
| 16 Sep | Lettmann Jason | CHIEF EXECUTIVE OFFICER | Acquired | P-Purchase | 21070 |